Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2025
|
| In: |
HemaSphere
Year: 2025, Jahrgang: 9, Heft: 3, Pages: 1-5 |
| ISSN: | 2572-9241 |
| DOI: | 10.1002/hem3.70099 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/hem3.70099
|
| Verfasserangaben: | Alexander Fosså, Daniel Molin, Paul J. Bröckelmann, Gundolf Schneider, Ulf Schnetzke, Johan Linderoth, Peter M.H. Kamper, Sirpa M. Leppä, Julia Meissner, Valdete Schaub, Kjersti Lia, Michael Fuchs, Peter Borchmann, Boris Böll |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1962684911 | ||
| 003 | DE-627 | ||
| 005 | 20260225144208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260225s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hem3.70099 |2 doi | |
| 035 | |a (DE-627)1962684911 | ||
| 035 | |a (DE-599)KXP1962684911 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fosså, Alexander |d 1968- |e VerfasserIn |0 (DE-588)172875412 |0 (DE-627)697804208 |0 (DE-576)133730689 |4 aut | |
| 245 | 1 | 0 | |a Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy |b Results from the prospective GHSG-NLG phase II BVB trial |c Alexander Fosså, Daniel Molin, Paul J. Bröckelmann, Gundolf Schneider, Ulf Schnetzke, Johan Linderoth, Peter M.H. Kamper, Sirpa M. Leppä, Julia Meissner, Valdete Schaub, Kjersti Lia, Michael Fuchs, Peter Borchmann, Boris Böll |
| 264 | 1 | |c March 2025 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.02.2026 | ||
| 700 | 1 | |a Molin, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bröckelmann, Paul J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneider, Gundolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schnetzke, Ulf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Linderoth, Johan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kamper, Peter M. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leppä, Sirpa M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 700 | 1 | |a Schaub, Valdete |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lia, Kjersti |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borchmann, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Böll, Boris |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d Hoboken : John Wiley & Sons Ltd., 2017 |g 9(2025), 3, Artikel-ID e70099, Seite 1-5 |h Online-Ressource |w (DE-627)1015324924 |w (DE-600)2922183-3 |w (DE-576)500571066 |x 2572-9241 |7 nnas |a Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy Results from the prospective GHSG-NLG phase II BVB trial |
| 773 | 1 | 8 | |g volume:9 |g year:2025 |g number:3 |g elocationid:e70099 |g pages:1-5 |g extent:5 |a Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy Results from the prospective GHSG-NLG phase II BVB trial |
| 856 | 4 | 0 | |u https://doi.org/10.1002/hem3.70099 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260225 | ||
| 993 | |a Editorial | ||
| 994 | |a 2025 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1962684911 |e 4922270590 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Alexander Fosså, Daniel Molin, Paul J. Bröckelmann, Gundolf Schneider, Ulf Schnetzke, Johan Linderoth, Peter M.H. Kamper, Sirpa M. Leppä, Julia Meissner, Valdete Schaub, Kjersti Lia, Michael Fuchs, Peter Borchmann, Boris Böll"]},"relHost":[{"corporate":[{"role":"isb","display":"European Hematology Association"}],"pubHistory":["Volume 1, issue 1 (December 2017)-"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2572-9241"],"zdb":["2922183-3"],"eki":["1015324924"]},"recId":"1015324924","note":["Gesehen am 18.01.2024"],"title":[{"subtitle":"open access journal of the European Hematology Association","title":"HemaSphere","title_sort":"HemaSphere"}],"part":{"issue":"3","year":"2025","extent":"5","volume":"9","pages":"1-5","text":"9(2025), 3, Artikel-ID e70099, Seite 1-5"},"language":["eng"],"disp":"Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy Results from the prospective GHSG-NLG phase II BVB trialHemaSphere","origin":[{"publisher":"John Wiley & Sons Ltd. ; Wolters Kluwer Health","dateIssuedDisp":"2024-","dateIssuedKey":"2024","publisherPlace":"Hoboken ; [Philadelphia, Pennsylvania]"}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"person":[{"display":"Fosså, Alexander","given":"Alexander","role":"aut","family":"Fosså"},{"display":"Molin, Daniel","given":"Daniel","family":"Molin","role":"aut"},{"given":"Paul J.","display":"Bröckelmann, Paul J.","family":"Bröckelmann","role":"aut"},{"role":"aut","family":"Schneider","given":"Gundolf","display":"Schneider, Gundolf"},{"display":"Schnetzke, Ulf","given":"Ulf","role":"aut","family":"Schnetzke"},{"display":"Linderoth, Johan","given":"Johan","family":"Linderoth","role":"aut"},{"role":"aut","family":"Kamper","given":"Peter M. H.","display":"Kamper, Peter M. H."},{"role":"aut","family":"Leppä","given":"Sirpa M.","display":"Leppä, Sirpa M."},{"family":"Meißner","role":"aut","display":"Meißner, Julia","given":"Julia"},{"family":"Schaub","role":"aut","display":"Schaub, Valdete","given":"Valdete"},{"given":"Kjersti","display":"Lia, Kjersti","role":"aut","family":"Lia"},{"display":"Fuchs, Michael","given":"Michael","family":"Fuchs","role":"aut"},{"role":"aut","family":"Borchmann","given":"Peter","display":"Borchmann, Peter"},{"given":"Boris","display":"Böll, Boris","role":"aut","family":"Böll"}],"physDesc":[{"extent":"5 S."}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"March 2025"}],"recId":"1962684911","id":{"doi":["10.1002/hem3.70099"],"eki":["1962684911"]},"title":[{"subtitle":"Results from the prospective GHSG-NLG phase II BVB trial","title":"Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy","title_sort":"Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy"}],"note":["Gesehen am 25.02.2026"]} | ||
| SRT | |a FOSSAALEXABRENTUXIMA2025 | ||